View More Recent Stories

Sep 14, 2016 06:16AM Exelixis (EXEL) Receives EC Approval of CABOMETYX as RCC Treatment Following VEGF-Targeted Therapy
Sep 14, 2016 01:00AM European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
Aug 31, 2016 08:35AM Exelixis (EXEL) Says Data from Trials of Cabozantinib and Cobimetinib Will be Subject of 15 Presentations at ESMO
Aug 31, 2016 08:30AM Exelixis-discovered Compounds To Be Featured in 15 Presentations at the ESMO 2016 Congress
Jul 22, 2016 10:30AM Exelixis (EXEL) and Ipsen Announces Positive CHMP Opinion for Cabometyx to Treat Advanced RCC
Jul 22, 2016 10:25AM Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy
Jun 6, 2016 07:35AM Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX™ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO A
Jun 6, 2016 07:30AM Exelixis (EXEL), Ipsen Announce Positive METEOR Trial Subgroup Analyses in RCC
Jun 6, 2016 07:30AM Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX™ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO A
Jun 5, 2016 07:53AM Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Re
Jun 5, 2016 07:35AM Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced re
May 23, 2016 02:31PM Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously un
May 23, 2016 09:05AM Exelixis (EXEL) Announces Cabozantinib Phase 2 Met Primary Endpoint in RCC
May 23, 2016 09:02AM Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell
Apr 25, 2016 01:54PM Exelixis (EXEL) Announces FDA Approval for CABOMETYX to Treat Advanced RCC
Apr 25, 2016 01:52PM Exelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Apr 25, 2016 01:52PM ADDING MULTIMEDIA Exelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Apr 20, 2016 12:10PM Exelixis (EXEL) Says New Data on Cabozantinib, Cobimetinib and XL888 Will Be Presented at ASCO
Apr 20, 2016 12:06PM Exelixis-Discovered Compounds to Be Featured in 18 Presentations at 2016 ASCO Annual Meeting
Sep 2, 2014 02:53PM Notable 52-Week Highs and Lows of the Day 9/2: (DGLY) (AAPL) (TSLA) High; (EXEL) (CONN) (MPEL) Low
View More Recent Stories